Scarica l'app Stockscreener
6.40
1.08%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$6.47
Aprire:
$6.51
Volume 24 ore:
108.76K
Relative Volume:
0.92
Capitalizzazione di mercato:
$678.62M
Reddito:
$117.05M
Utile/perdita netta:
$-3.71M
Rapporto P/E:
-82.16
EPS:
-0.0779
Flusso di cassa netto:
$1.67M
1 W Prestazione:
-5.33%
1M Prestazione:
-4.33%
6M Prestazione:
-20.20%
1 anno Prestazione:
-27.85%
Intervallo 1D:
$6.40
$6.65
Intervallo di 1 settimana:
$6.40
$7.09
Portata 52W:
$5.44
$9.42
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Nome
Gyre Therapeutics Inc
Settore
Industria
Telefono
(858) 284-0115
Indirizzo
12730 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
6.40 | 678.62M | 117.05M | -3.71M | 1.67M | -0.0779 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | Jefferies | Buy |
| 2025-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-11 | Iniziato | Noble Capital Markets | Outperform |
| 2021-04-29 | Ripresa | Stephens | Overweight |
| 2021-02-10 | Iniziato | Piper Sandler | Overweight |
| 2020-05-21 | Iniziato | Raymond James | Outperform |
| 2019-01-04 | Iniziato | Oppenheimer | Outperform |
| 2018-02-12 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Reiterato | Chardan Capital Markets | Buy |
| 2017-12-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Iniziato | Chardan Capital Markets | Buy |
| 2017-06-06 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-06-30 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Gyre Therapeutics Inc Borsa (GYRE) Ultime notizie
GYRE Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesTax Rate Impact - dars.gov.et
Gyre Therapeutics stock posts double digit 12 month gain as investors watch pipeline progress - AD HOC NEWS
Solid Biosciences (Nasdaq:SLDB)Stock Analysis - Simply Wall Street
Gyre Therapeutics stock holds steady as investors await next clinical and earnings milestones - AD HOC NEWS
Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Detailed Stock Data - The Chronicle-Journal
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 159.98% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Stock Quote - The Chronicle-Journal
Gyre Therapeutics Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Rise 6.57%EBITDA Margin Trends - www.dars.gov.et
Gyre Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Gyre Therapeutics to Participate in Upcoming September Investor Conferences - marketscreener.com
Two live online healthcare talks will feature Gyre Therapeutics this month - Stock Titan
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy - The Globe and Mail
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy - TipRanks
Gyre updates corporate presentation, outlines China-driven R&D and F351 regulatory progress - TradingView
Gyre Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Gyre Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Gyre Therapeutics unveils capital-efficient global development strategy - The Globe and Mail
Gyre Therapeutics unveils capital-efficient global development strategy - TipRanks
Gyre Therapeutics posts updated corporate presentation detailing pipeline progress and China-commercial revenue drivers - TradingView
Gyre (GYRE) Results Review: The EPS Result Is Below Expectation in the Latest Session; After Results: Shares Move 1.82% Down for the Current SessionBalance Sheet Strength - vinanet.vn
Gyre (GYRE): Slides 2.10% to $7.00 in Latest Trading; Trading Range: Price Remains Between $6.65 Support and $7.35 ResistanceBackspread Trade - vinanet.vn
Gyre Therapeutics (NASDAQ:GYRE) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Palomar (PLMR) Results Check: EPS Clears the Reported Estimate in the Latest Session; Market Response: Shares Move 0.92% LowerMargin Improvement Report - careplusvn.com
Gyre (GYRE): Slides 2.10% to $7.00 in Latest Trading; Trading Range: Price Remains Between $6.65 Support and $7.35 ResistanceMedian Line - siam.in
Analysts Set Expectations for GYRE Q3 Earnings - MarketBeat
GYRE | Gyre Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Claire Weston Net Worth (2026) - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN) - The Globe and Mail
Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Gyre Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gyre Therapeutics earnings missed by $0.06, revenue topped estimates - Investing.com Nigeria
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Lights a Fire Under SharesEarnings Surprise Score - vinanet.vn
Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results - MarketBeat
Gyre Therapeutics earnings missed by $0.06, revenue topped estimates - Investing.com Canada
Form 8K Gyre Therapeutics Inc For: 7 August By Investing.com - Investing.com Nigeria
GYRE: Net loss widened to $32.8 million on $53.5 million revenue, with strong liquidity maintained - TradingView
Gyre Therapeutics (NASDAQ: GYRE) swings to 32,849 H1 2026 net loss - Stock Titan
Gyre Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Gyre Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gyre Therapeutics Q2 EPS misses estimate despite sales beat - scanx.trade
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Gyre Therapeutics Sees 2026 Rev $100.5M-$111.0M >GYRE - Moomoo
Gyre Therapeutics Reports Second Quarter 2026 - Moomoo
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Form 8K Gyre Therapeutics Inc For: 7 August By Investing.com - Investing.com Canada
GYRE Q2 Revenue Falls To $29.1 Million As Net Loss Widens - Quiver Quantitative
GYRE: Q2 2026 revenue reached $29.1M, net loss widened, and Cullgen acquisition expanded the pipeline - TradingView
Gyre Therapeutics reports Q2 2026 revenue $29.1M, GAAP EPS $(0.12); full-year revenue guidance affirmed - TradingView
Gyre Therapeutics Inc Azioni (GYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gyre Therapeutics Inc Azioni (GYRE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ye Weiguo | Chief Operating Officer |
Jun 18 '26 |
Sale |
6.35 |
3,000 |
19,050 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 11 '26 |
Sale |
6.17 |
2,800 |
17,276 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 11 '26 |
Option Exercise |
0.75 |
2,800 |
2,100 |
702,800 |
| Ye Weiguo | Chief Operating Officer |
Jun 10 '26 |
Sale |
6.21 |
6,418 |
39,856 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 10 '26 |
Sale |
6.24 |
5,000 |
31,200 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 10 '26 |
Option Exercise |
0.75 |
6,418 |
4,814 |
706,418 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Sale |
6.14 |
14,500 |
89,030 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Sale |
6.15 |
3,000 |
18,450 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Option Exercise |
0.75 |
14,500 |
10,875 |
714,500 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Option Exercise |
0.75 |
3,000 |
2,250 |
703,000 |
0.10%
3.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):